Arcus Biosciences(RCUS)

HAYWARD, CABiotechnology7 H-1B visas (FY2023)

Focus: Arcus Biosciences is a publicly-traded oncology-focused immunotherapy company headquartered in Hayward, CA, developing novel cancer treatments across multiple tumor types. The company operates as a mid-cap biotech with a diversified pipeline emphasizing immuno-oncology mechanisms.

Oncology

Profile data last refreshed 3h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Arcus Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Arcus Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$117M

Key Products

Atezolizumab

Prostate Cancer

Growth

Phase 2 program suggesting potential combination/expansion strategy in solid tumors.

Pipeline & Clinical Trials

Help build intelligence for Arcus Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep focus on cancer immunotherapies with 10 pipeline programs across Phase 1-3, including 2 Phase 3 programs (zimberelimab, casdatifan, quemliclustat) with near-term catalysts
Strong R&D commitment with 291% R&D intensity, indicating aggressive investment in drug development and scientific advancement
Public company status with proven capital markets access ($150M cash position in FY2025) and demonstrated ability to fund pipeline progression

Watch Out For

Significant financial burn with $307M net loss in FY2025 against only $117M revenue—runway concerns if clinical programs delay
Zero active job postings at time of analysis suggests no near-term hiring growth or potential organizational contraction
Early-stage pipeline heavy (11 Phase 1 programs vs. only 2 Phase 3) means product approval and revenue inflection are years away

Generated by Claude from Arcus Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement

Hip Replacement Arthroplasty

Clinical Trials (1)

NCT01394744Determination of Metal Ion Serum Levels and Cytokines in Total Hip Replacement

N/A

IPI-549

Triple-Negative Breast Cancer

Phase 1

Clinical Trials (1)

NCT03719326A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Phase 1

AB598

Advanced Cancer

Phase 1

zanzalintinib

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

Phase 1

Clinical Trials (1)

NCT06191796Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Phase 1

AB680

Pancreatic Cancer

Phase 1

Clinical Trials (3)

NCT04104672A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies

Phase 1

NCT04575311A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Phase 1

NCT03677973A Study to Investigate the Safety of AB680 in Healthy Volunteers

Phase 1

AB801

Advanced Cancer

Phase 1

Clinical Trials (2)

NCT06004921A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers

Phase 1

NCT06120075A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Phase 1

etrumadenant

Non-small Cell Lung Cancer

Phase 2

Clinical Trials (5)

NCT04791839Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2

NCT06048484Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Phase 2

NCT05915442Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Phase 2

+2 more

Atezolizumab

Prostate Cancer

Phase 2

domvanalimab

Hepatobiliary Cancer

Phase 2

quemliclustat

Pancreatic Cancer

Phase 3

Clinical Trials (3)

NCT06608927Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 3

NCT05688215Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1/2

NCT07364214Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Phase 1

zimberelimab

Hepatobiliary Cancer

Phase 3

Clinical Trials (5)

NCT05130177Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Phase 2

NCT05724563Domvanalimab and Zimberelimab in Advanced Liver Cancers

Phase 2

NCT07283848Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2

+2 more

casdatifan

Renal Cell Carcinoma

Phase 3

Clinical Trials (5)

NCT07011719Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase 3

NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2

NCT05117554Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

Phase 1

+2 more

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 32 clinical trials

Top TAs: Oncology

H-1B (2023): 7 approvals

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

24 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$117M4%

R&D Spend

$340M(291%)18%

Net Income

-$307M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo